These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

897 related items for PubMed ID: 27842901

  • 1. Comparison of heparin, bivalirudin, and different glycoprotein IIb/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis.
    Lipinski MJ, Lee RC, Gaglia MA, Torguson R, Garcia-Garcia HM, Pichard AD, Satler LF, Waksman R.
    Cardiovasc Revasc Med; 2016 Dec; 17(8):535-545. PubMed ID: 27842901
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ, TENACITY Steering Committee and Investigators.
    Catheter Cardiovasc Interv; 2011 Jun 01; 77(7):1001-9. PubMed ID: 21598351
    [Abstract] [Full Text] [Related]

  • 4. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    Lincoff AM, Steinhubl SR, Manoukian SV, Chew D, Pollack CV, Feit F, Ware JH, Bertrand ME, Ohman EM, Desmet W, Cox DA, Mehran R, Stone GW, Acute Catheterization and Urgent Intervention Triage strategY of Trial Investigators.
    JACC Cardiovasc Interv; 2008 Dec 01; 1(6):639-48. PubMed ID: 19463378
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
    Valgimigli M, Frigoli E, Leonardi S, Vranckx P, Rothenbühler M, Tebaldi M, Varbella F, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andó G, Ferrario M, Limbruno U, Garbo R, Sganzerla P, Russo F, Nazzaro M, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Ferrante G, Santarelli A, Sardella G, de Cesare N, Tosi P, van 't Hof A, Omerovic E, Brugaletta S, Windecker S, Heg D, Jüni P, MATRIX Investigators.
    Lancet; 2018 Sep 08; 392(10150):835-848. PubMed ID: 30153988
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study.
    Cortese B, Micheli A, Picchi A, Bandinelli L, Brizi MG, Severi S, Limbruno U.
    Coron Artery Dis; 2009 Aug 08; 20(5):348-53. PubMed ID: 19543084
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
    Bangalore S, Toklu B, Kotwal A, Volodarskiy A, Sharma S, Kirtane AJ, Feit F.
    BMJ; 2014 Nov 11; 349():g6419. PubMed ID: 25389143
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of anti-thrombotic strategies using Bivalirudin, Heparin plus Glycoprotein IIb/IIIa inhibitors and Unfractionated Heparin Monotherapy for patients undergoing percutaneous coronary intervention - A single centre observational study.
    Kaul U, Dua A, Sethi AK, Arambam P, Seth A.
    Indian Heart J; 2015 Nov 11; 67(4):311-7. PubMed ID: 26304562
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
    Feldman DN, Minutello RM, Bergman G, Moussa I, Wong SC.
    Catheter Cardiovasc Interv; 2010 Oct 01; 76(4):513-24. PubMed ID: 20882655
    [Abstract] [Full Text] [Related]

  • 14. Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population.
    Shelton R, Eftychiou C, Somers K, Liu A, Burton-Wood N, Anderson M, Makri L, Blaxill J, McLenachan J, Wheatcroft S, Greenwood J, Blackman D.
    EuroIntervention; 2013 May 20; 9(1):118-24. PubMed ID: 23410540
    [Abstract] [Full Text] [Related]

  • 15. Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography).
    Clemmensen P, Wiberg S, Van't Hof A, Deliargyris EN, Coste P, Ten Berg J, Cavallini C, Hamon M, Dudek D, Zeymer U, Tabone X, Kristensen SD, Bernstein D, Anthopoulos P, Prats J, Steg PG.
    JACC Cardiovasc Interv; 2015 Jan 20; 8(1 Pt B):214-220. PubMed ID: 25616927
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Utilization of anticoagulants and outcomes in STEMI patients undergoing PPCI in the US hospitals: Bivalirudin, heparin plus GPI or heparin alone?
    Plent S, Mitchell M, Fan W, Werner R.
    Hosp Pract (1995); 2015 Jan 20; 43(3):164-71. PubMed ID: 26190670
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention.
    Deshpande NV, Pratiti R, Admane P, Mukherjee D, Mardikar HM.
    Indian Heart J; 2012 Jan 20; 64(5):444-8. PubMed ID: 23102380
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.